Abstract
Introduction: Previous work has showed the in vivo presence of retinal amyloid in Alzheimer's disease (AD) patients using curcumin. We aimed to replicate these findings in an amyloid biomarker-confirmed cohort.
Methods: Twenty-six patients with AD (age 66 [+9], Mini-Mental Status Examination [MMSE] ≥17) and 14 controls (age 71 [+12]) used one of three curcumin formulations: Longvida, Theracurmin, and Novasol. Plasma levels were determined and pre- and post-curcumin retinal fluorescence scans were assessed visually in all cases and quantitatively assessed in a subset.
Results: Visual assessment showed no difference between AD patients and controls for pre- and post-curcumin images. This was confirmed by quantitative analyses on a subset. Mean conjugated plasma curcumin levels were 198.7 nM (Longvida), 576.6 nM (Theracurmin), and 1605.8 nM (Novasol).
Discussion: We found no difference in retinal fluorescence between amyloid-confirmed AD cases and control participants, using Longvida and two additional curcumin formulations. Additional replication studies in amyloid-confirmed cohorts are needed to assess the diagnostic value of retinal fluorescence as an AD biomarker.
| Original language | English |
|---|---|
| Article number | e12347 |
| Pages (from-to) | e12347 |
| Journal | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2022 |
Keywords
- Alzheimer's disease
- amyloid
- biomarker
- curcumin
- retina
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol. 14, No. 1, e12347, 2022, p. e12347.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - No difference in retinal fluorescence after oral curcumin intake in amyloid-proven AD cases compared to controls
AU - den Haan, Jurre
AU - Hart de Ruyter, Frederique J
AU - Lochocki, Benjamin
AU - Kroon, Maurice A G M
AU - Kemper, E Marleen
AU - Teunissen, Charlotte E
AU - van Berckel, Bart
AU - Scheltens, Philip
AU - Hoozemans, Jeroen J
AU - van de Kreeke, Aleid
AU - Verbraak, Frank D
AU - de Boer, Johannes F
AU - Bouwman, Femke H
N1 - Funding Information: The research of C.T. is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 [MIRIADE], and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer's Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer's Association. C.T. is recipients of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes‐Strijbisfonds. C.T. has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly; and has performed contract research or received grants from AC‐Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, and Vivoryon. F.B. has a collaboration contract with Biogen, Optina Dx, and Roche. Payments are made to the institution of VUMC. F.B. is committee member of EAN and chairs the atypical AD PIA and the Eye as biomarker for AD PIA of ISTAART. P.S. is chair of the steering committee in NOVARTIS, member of DSMB GENENTECH, global PI phase s! study AC IMMUNE, member advisory board AXON NEUROSCIENCE, global PI phase 2B study EIP PHARMA, PI phase 2B study COGRX, member advisory board GEMVAX, COGNOPTIX, and CORTEXZYME, member strategic innovation committee GREEN VALLEY, PI global phase 2B study Vivoryon, PI global phase 2A study TOYAMA/FUJI FILM, PI global phase 1A study IONIS, personal fees from Life Science Partners Amsterdam, outside the submitted work. J.B. is supported for the current study by NWO (Foundation for scientific research in the Netherlands, similar to NIH and NSF) and Co‐financing by Heidelberg engineering as part of the competitive research proposal, administered by the funding agency. Both these fundings are paid to institution. Besides this study J.B. received in the past 36 months research grants from Heidelberg, topconsortia voor kennis en innovatie (TKI), nederlandse organisatie voor toegepast‐natuurwetenschappelijk onderzoek (TNO), and LSHM paid to institution. Personal fees from royalties through former employer, Massachusetts general Hospital, for IP that has been licensed to Terumo, Heidelberg engineering and Spectrawave as well as fees for expert witness for a UK based law firm. He is program committee member for a number of conferences, unpaid. J.dH., B.L., F.H., M.K., M.K., B.B., J.H., A.K., and F.V. report no conflict of interest and have nothing to disclose. Author disclosures are available in the supporting information. Funding Information: We gratefully acknowledge financial support from Stichting Alzheimercentrum VUMC, Alzheimer Nederland, the Dutch Technology Foundation STW (grant number 13935), part of the Netherlands Organization for Scientific Research (NWO), and which is partly funded by the Ministry of Economic Affairs, ISAO (grant number 14518). Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: Previous work has showed the in vivo presence of retinal amyloid in Alzheimer's disease (AD) patients using curcumin. We aimed to replicate these findings in an amyloid biomarker-confirmed cohort.Methods: Twenty-six patients with AD (age 66 [+9], Mini-Mental Status Examination [MMSE] ≥17) and 14 controls (age 71 [+12]) used one of three curcumin formulations: Longvida, Theracurmin, and Novasol. Plasma levels were determined and pre- and post-curcumin retinal fluorescence scans were assessed visually in all cases and quantitatively assessed in a subset.Results: Visual assessment showed no difference between AD patients and controls for pre- and post-curcumin images. This was confirmed by quantitative analyses on a subset. Mean conjugated plasma curcumin levels were 198.7 nM (Longvida), 576.6 nM (Theracurmin), and 1605.8 nM (Novasol).Discussion: We found no difference in retinal fluorescence between amyloid-confirmed AD cases and control participants, using Longvida and two additional curcumin formulations. Additional replication studies in amyloid-confirmed cohorts are needed to assess the diagnostic value of retinal fluorescence as an AD biomarker.
AB - Introduction: Previous work has showed the in vivo presence of retinal amyloid in Alzheimer's disease (AD) patients using curcumin. We aimed to replicate these findings in an amyloid biomarker-confirmed cohort.Methods: Twenty-six patients with AD (age 66 [+9], Mini-Mental Status Examination [MMSE] ≥17) and 14 controls (age 71 [+12]) used one of three curcumin formulations: Longvida, Theracurmin, and Novasol. Plasma levels were determined and pre- and post-curcumin retinal fluorescence scans were assessed visually in all cases and quantitatively assessed in a subset.Results: Visual assessment showed no difference between AD patients and controls for pre- and post-curcumin images. This was confirmed by quantitative analyses on a subset. Mean conjugated plasma curcumin levels were 198.7 nM (Longvida), 576.6 nM (Theracurmin), and 1605.8 nM (Novasol).Discussion: We found no difference in retinal fluorescence between amyloid-confirmed AD cases and control participants, using Longvida and two additional curcumin formulations. Additional replication studies in amyloid-confirmed cohorts are needed to assess the diagnostic value of retinal fluorescence as an AD biomarker.
KW - Alzheimer's disease
KW - amyloid
KW - biomarker
KW - curcumin
KW - retina
UR - http://www.scopus.com/inward/record.url?scp=85145102846&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/dad2.12347
DO - https://doi.org/10.1002/dad2.12347
M3 - Article
C2 - 35991218
SN - 2352-8729
VL - 14
SP - e12347
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
IS - 1
M1 - e12347
ER -